Europe Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report by Type, Country and Growth Forecast, 2022-2028

The Europe Gastroesophageal Reflux Disease Therapeutics Market should witness market growth of 1.8% CAGR during the forecast period (2022-2028).

GERD reduces chemical clearance because of the bicarbonates in saliva. The importance of esophageal clearance has recently been shown, even in neonates, where it helps to foretell how well PPI medication would work. It was seen that among neonates with longer acid esophageal exposure times, more effective and quick esophageal clearance as measured by impedance-pH monitoring was substantially related to a favorable clinical response to omeprazole anti-reflux medication (AET).

Some GERD patients are known to have delayed gastric emptying, which may promote the backflow of the stomach material. There is no indication of stomach acid hypersecretion in these individuals, even though the mainstay of GERD therapy is using antisecretory medicines to minimize acid reflux. The most aggressive element in identifying mucosal damage or reflux symptoms continues to be acid. Smoking regularly is regarded as a risk factor for the development of GERD.

Individuals in the least poor regions were likelier than adults in the most deprived areas to consume more than 14 units of alcohol in a typical week. Although younger individuals are less likely than any other age group to drink, the research shows that when they do, their consumption is more likely to be greater than that of older persons on their busiest drinking day. According to a 2015 Italian Ministry of Health assessment, 64.5% of Italians over 11 have used alcohol at least once, with men outnumbering women. The rising frequency of people consuming alcohol is expected to increase the prevalence of digestive illnesses like gastroesophageal reflux and drive the market's expansion.

The Germany market dominated the Europe Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $373.3 Million by 2028. The UK market is anticipated to grow at a CAGR of 1% during (2022-2028). Additionally, The France market would exhibit a CAGR of 2.5% during (2022-2028).

Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

By Type

• Antacids
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Blockers
• Pro-kinetic Agents

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• AstraZeneca PLC
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigus Ltd.
• Sebela Pharmaceuticals
• Phathom Pharmaceuticals, Inc.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free